Fixed combination trandolapril/verapamil sustained-release: A review of its use in essential hypertension

Drugs

Volumn 62, Issue 17, 2002, Pages 2539-2567

  Muijsers, Richard B R ^a   Curran, Monique P ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL PLUS CHLORTALIDONE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; TRANDOLAPRIL; TRANDOLAPRILAT; VERAPAMIL;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; REVIEW; SENESCENCE; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDOLES; MEDLINE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VERAPAMIL;

ANGINA;

EID: 0036453628     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
2. Alderman M, Arakawa K, Beilin L, et al. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press 1999; 8 Suppl. 1: 9-43
3. Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999 Sep; 13: 569-92
4. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002; 62 (3): 443-62
5. Peters DC, Noble S, Plosker GL. Trandolapril: An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 1998 Nov; 56: 871-93
6. Wiseman LR, McTavish D. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994 Jul; 48 (1): 71-90
7. Brogden RN, Benfield P. Verapamil: A review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 1996 May: 51: 792-819
8. McTavish D, Sorkin EM. Verapamil: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989 Jul; 38 (1): 19-76
9. Dooley M, Goa KL. Fixed combination trandolapril/verapamil SR. Drugs 1998 Nov; 56 (5): 837-44; discussion 845-6
10. Petrie JR, Morris AD, Ueda S, et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: A double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000 May; 85 (5): 1882-9
11. Galletti F, Strazzullo P, Capaldo B, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999 Mar; 17: 439-45
12. New JP, Bilous RW, Walker M. Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diabet Med 2000 Feb; 17 (2): 134-40
13. Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: The VAMPHYRE study. Am J Hypertens 2001 Nov; 14 (11 Pt 1): 1083-9
14. Nazzaro P, Manzari M, Merlo M, et al. Antihypertensive treatment with verapamil and amlodipine: Their effect on the functional autonomic and cardiovascular stress responses. Eur Heart J 1995 Sep; 16 (9): 1277-84
15. Schussheim AE, Diamond JA, Phillips RA. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol 2001 Jan 1; 87: 61-5
16. Abbott Laboratories. Trandolapril [Package Insert]: US Prescribing Information. 2001
17. Abbott Laboratories. TARKA (Trandolapfil/Verapamil Hydrochloride ER Tablets): US Full Prescribing Information. 2001
18. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001 Jul 31; 104 (5): e14-8
19. Ruschitzka FT, Lüscher TF. Concept for a combination of ACE inhibitors and calcium antagonists in cardiovascular disease. J Cardiovasc Pharmacol 1997; 30 Suppl. 1: S10-23
20. Ferrari R. Angiotensin converting enzyme inhibitor-calcium antagonist combination: An alliance for cardioprotection? J Hypertens 1997 Mar; 15 Suppl. 2: S109-117
21. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: Putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Drugs 1999 Oct; 58 (4): 579-87
22. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997 Dec 1; 80 (11): 1453-8
23. Viskoper RJ, Compagnone D, Dies R, et al. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Curr Ther Res 1997; 58 (6): 343-51
24. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: A double-blind, placebo-controlled parallel group study. J Hypertens 1997 Jan; 15 (1): 87-91
25. Breithaupt-Grögler K, Gerhardt G, Lehmann G, et al. Blood pressure and aortic elastic properties - Verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther 1998 Aug; 36 (8): 425-31
26. Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: The Veratran study. Am J Hypertens 1997; 10 (5): 492-9
27. Ramos F, Baglivo H, Sánchez R. Comparative double blind study at fixed dose of trandolapfil + verapamil vs atenolol + chlortalidone in mild to moderate hypertensive patients [abstract]. J Hypertens 2001 Jun; 19 Suppl. 2: S236
28. Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999 May; 30 (5): 1056-64
29. Messerli FH, Soria F. Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death. Cardiovasc Drugs Ther 1994 Aug; 8 Suppl. 3: 557-63
30. Aepfelbacher FC, Messerli FH, Nunez E, et al. Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Am J Cardiol 1997 Mar 15; 79 (6): 826-8
31. Adalet K, Oflaz H, Sezer A, et al. Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial. Curr Ther Res Clin Exp 2001 Apr; 62: 261-71
32. Hansen JF, Tingsted L, Rasmussen V, et al. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol 1996; 77: 16D-21D
33. Mitrovic V, Parzeller M, Notter T, et al. Antihypertensive combination treatment with Verapamil SR 180 mg/Trandolapril 2 mg preserves left ventricular function in NYHA class I and II heart failure patients [abstract]. Cardiovasc Drugs Ther 1999 Mar; 13: 38
34. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997; 79: 738-41
35. Hansen JF, Hagerup L, Sigurd B, et al. Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. Am Heart J 1997 Aug; 134 (2 Pt 2): S48-52
36. Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996 May; 14 (5): 669-77
37. Fernández R, Puig JG, Rodríguez-Pérez JC, et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: A randomised, double-blind study. J Hum Hypertens 2001 Dec; 15 (12): 849-56
38. Cifková R, Nakov R, Novozámská E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000 Jun; 14 (6): 347-54
39. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001 Jan 6; 322 (7277): 15-8
40. Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998 Oct; 54 (4): 1283-9
41. Rubio-Guerra AF, Treviño-Gomezharper C, Rodríguez-López L, et al. Renoprotective effects of the combination trandolapril/ verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002; 22 (8): 541-6
42. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomized double-blind trial. J Hypertens 2002 Apr; 20 (4): 729-37
43. Siepmann M, Rao BR, Kirch W. Disposition, elimination and haemodynamic effects of verapamil and trandolapril in patients with fatty liver disease. Clin Drug Invest 1997 Nov; 14: 376-82
44. Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S50-9
45. Lenfant B, Mouren M, Bryce T, et al. Trandolapril: Pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol 1994; 23 Suppl 4.: S38-43
46. Abbott Laboratories. Isoptin SR (Verapamil HCL): US Prescribing Information. 2002
47. Sever PS, de Chatel R, Cifkova R, et al. Antihypertensive efficacy and safety of verapamil SR/trandolapril (2/240 mg) in patients insufficiently pretreated with verapamil SR 240 mg monotherapy [abstract]. Am J Hypertens 1999 Apr; 12 (Pt 2): 135A
48. Beevers DG, Gallet M, Middeke M, et al. Efficacy and safety of the fixed combination trandolapril/verapamil SR 2/180 mg in hypertensive patients insufficiently pretreated with trandolapril 2 mg monotherapy [abstract no. E019]. Am J Hypertension 1998; 11 (4) Pt 2:100a
49. DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. Am J Hypertens 1997 Jul; 10 (7 Pt 2): 138S-45S
50. DeQuattro V, Lee D, Messerli F. Efficacy of combination therapy with trandolapril and verapamil SR in primary hypertension: A 4 × 4 trial design. Trandolapril Study Group. Clin Exp Hypertens 1997 Apr; 19 (3): 373-87
51. Viskoper RJ, Compagnone D, Dies R, et al. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: A multicenter, double-masked study. Curr Ther Res 1997; 58 (6): 331-42
52. Messerli F, Frishman WH, Elliott WJ, et al. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998 Mar; 11 (3 Pt 1): 322-7
53. Karlberg BE, Andrup M, Odén A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000: 9 (2-3): 140-5
54. Skoularigis J, Strugo V, Radevski I, et al. Once-daily fixed dose combinations of verapamil and trandolapril in Black patients with mild to moderate hypertension: A new choice for first line treatment. Int J Clin Pharmacol Ther 1997 Feb; 35 (2): 51-5
55. Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension-a clinical trial of factorial design. German Hypertension Study Group. Br J Clin Pharmacol 1998 May; 45 (5): 491-5
56. Ruilope LM, Gascueña R, Investigators' Group. Treating highnormal and borderline isolated systolic hypertension in type-2 diabetic patients. Combined versus monotherapy [abstract]. Proceedings of the 38th Annual Meeting of the European Association for the Study of Diabetes; 2002 Sept; Budapest, Hungary, Diabetologia 2002; 45 Suppl. 2: A368-9
57. Ruilope LM, de la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: The EDICTA study. J Hypertens 1999 Dec; 17 (Prt 2): 1917-23
58. Kaufman JS, Tracy JA, Durazo-Arvizu RA, et al. Lifestyle, education, and prevalence of hypertension in populations of African origin. Results from the International Collaborative Study on Hypertension in Blacks. Ann Epidemiol 1997 Jan; 7 (1): 22-7
59. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common? Ann Epidemiol 1996 May; 6 (3): 173-80
60. Hall WD. A rational approach to the treatment of hypertension in special populations. Am Fam Physician 1999 Jul; 60 (1): 156-62
61. Punzi HA, Novrit BA. The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. J Hum Hypertens 1997 Aug; 11 (8): 477-81
62. Holzgreve H. Compagnone D, Zilles P. Trandolapril/verapamil SR combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. J Hum Hypertens 1999 Jan; 13 (1): 61-7
63. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl. 1997 Mar; 15 (2): S51-3
64. Watling SM, Crain JL, Edwards TD, et al. Verapamil overdose: Case report and review of the literature. Ann Pharmacother 1992 Nov; 26 (11): 1373-8
65. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: A literature review of overdoses and discussion of therapeutic options. Am J Med 1993 Oct; 95 (4): 431-8
66. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: A report of two cases and a review of the literature. Am J Emerg Med 1989 Nov; 7 (6): 624-31
67. Ashraf M, Chaudhary K, Nelson J, et al. Massive overdose of sustained-release verapamil: A case report and review of literature. Am J Med Sci 1995 Dec; 310 (6): 258-63
68. Abbott Laboratories. TARKA Summary of Product Characteristics. 2002
69. Donahue S, Lachman L, Norton J, et al. Verapamil significantly increases serum concentrations of simvastatin but not pravastatin. Clin Pharmacol Ther 1999; 65 (2): 179
70. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998 Aug; 64 (2): 177-82
71. Schwartz GL, Sheps SG. A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Curr Opin Cardiol 1999 Mar; 14: 161-8
72. Carretero OA, Oparil S. Essential hypertension: Part II: Treatment. Circulation 2000 Feb 1; 101 (4): 446-53
73. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201
74. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes; a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Disease 2000; 36: 646-61
75. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary. BMJ 2000 Mar 11; 320 (7236): 705-8
76. Ram CVS. Antihypertensive drugs; an overview. Am J Cardiovasc Drugs 2002; 2 (2): 77-89
77. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
78. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 Sep 12; 317 (7160): 703-13
79. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Meal 1998 Mar 5; 338 (10): 645-52
80. Ruzicka M, Leenen FHH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61 (7): 943-54
81. Neutel JM. Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management. Am J Hypertens 1999 Aug; 12 (8 Pt 2): 73S-9S
82. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998 Dec 31; 339 (27): 1957-63
83. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998 Jun; 11 (6 Pt 2): 73S-8S; discussion 95S-100S
84. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: Recommendations for use. Am Fam Physician 2000; 61 (10): 3049-56
85. AstraZeneca. Unimax (Felodipine - Ramipril): US Prescribing Information [on line]. Available from URL: http://astra-zeneca.com [Accessed 2002 Oct 25]
86. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995 Jul; 26 (1): 143-9
87. Epstein M. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: Focus on fixed-dose combination antihypertensive therapy. Ren Fail 1996 Nov; 18 (6): 813-32
88. Bakris GL. The role of combination antihypertensive therapy and the progression of renal disease hypertension: Looking toward the next millennium. Am J Hypertens 1998 Oct; 11 (10): 158S-62S
89. Taylor AA, Sunthornyothin S. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers. Curr Hypertens Rep 1999 Oct; 1 (5): 446-53
90. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002; 25 Suppl. 1: S85-9
91. Ruggenenti P, Remuzzi G. Primary prevention of renal function in diabetic patients: The Bergamo Nephrologic Diabetes Complication Trial. Bergamo Diabetic Nephropathy Study Group. J Hypertens 1998; 16 Suppl. 1: S95-7
92. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998 Nov; 32 (5): 1228-37